PMID- 18953508
OWN - NLM
STAT- MEDLINE
DCOM- 20090210
LR  - 20131121
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Linking)
VI  - 127
IP  - 2
DP  - 2009 Feb
TI  - Serum zinc and copper levels in ischemic cardiomyopathy.
PG  - 116-23
LID - 10.1007/s12011-008-8237-1 [doi]
AB  - Changes in the copper (Cu) and zinc (Zn) concentrations have been reported 
      previously in ischemic cardiomyopathy (ISCMP). Due to controversial results, the 
      aims of this study were to compare levels of Cu, Zn, and Zn/Cu ratio of ISCMP 
      patients with healthy volunteers and also to investigate the possible 
      relationship between trace elements status in ISCMP patients with the severity of 
      clinical disease based on the New York Heart Association (NYHA) classification. 
      The subjects of this study consisted of 30 ISCMP and 27 healthy volunteers. ISCMP 
      was diagnosed with a history of previous myocardial infarction and also coronary 
      artery disease was confirmed by coronary angiography. Exclusion criteria were 
      renal or hepatic insufficiency, alcohol usage, and intake of supplements 
      containing Cu or Zn within 1 week. Cu and Zn levels have been assayed with atomic 
      absorption spectrophotometry. Statistical analysis was performed with the SPSS 10 
      software using independent sample t test for comparing the levels of Cu and Zn 
      between ISCMP and normal subjects. The mean Cu level of the ISCMP group (1.54 +/- 
      0.52 mg/L) was significantly more than the Cu levels of the healthy volunteers 
      (1.31 +/- 0.24 mg/L; p = 0.048). The mean Zn levels of the ISCMP and healthy 
      volunteers were 1.05 +/- 0.28 and 1.12 +/- 0.42, respectively, without any 
      significant difference between groups. There was a trend for higher Cu level, 
      lower Zn level, and lower Zn/Cu ratio in NYHA III patients in comparison with 
      NYHA II group. Considering the results of this study, Cu may have a role in the 
      development of ISCMP. Interventions such as administration of Cu chelators to 
      relieve the symptoms or to decrease the progression of ISCMP is needed to be 
      examined in large clinical trials. In this study, the Zn level of ISCMP patients 
      was not significantly different in comparison with the healthy volunteers.
FAU - Shokrzadeh, Mohammad
AU  - Shokrzadeh M
AD  - Department of Toxicology, Faculty of Pharmacy, Mazandaran Pharmaceutical Sciences 
      Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
FAU - Ghaemian, Ali
AU  - Ghaemian A
FAU - Salehifar, Ebrahim
AU  - Salehifar E
FAU - Aliakbari, Soudabeh
AU  - Aliakbari S
FAU - Saravi, Seyyed Soheil Saeedi
AU  - Saravi SS
FAU - Ebrahimi, Pooneh
AU  - Ebrahimi P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081025
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
RN  - 789U1901C5 (Copper)
RN  - J41CSQ7QDS (Zinc)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cardiomyopathies/*blood
MH  - Copper/*blood
MH  - Coronary Angiography
MH  - Female
MH  - Heart Failure/blood/classification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*blood
MH  - Spectrophotometry, Atomic
MH  - Zinc/*blood
EDAT- 2008/10/28 09:00
MHDA- 2009/02/12 09:00
CRDT- 2008/10/28 09:00
PHST- 2008/08/05 00:00 [received]
PHST- 2008/09/15 00:00 [accepted]
PHST- 2008/10/28 09:00 [pubmed]
PHST- 2009/02/12 09:00 [medline]
PHST- 2008/10/28 09:00 [entrez]
AID - 10.1007/s12011-008-8237-1 [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 2009 Feb;127(2):116-23. doi: 10.1007/s12011-008-8237-1. Epub 
      2008 Oct 25.